Novartis Halts CAR-T Trials After Fatalities, Reports MS Drug Success

Note: This section contains information in English only.
Source: Dukascopy Bank SA
Novartis has paused eight clinical trials for experimental CAR-T therapies targeting autoimmune and neurological diseases following the deaths of three patients from severe immune reactions. The company is investigating the cases alongside safety boards and regulators. Bristol-Myers Squibb has paused similar studies as a precaution.



In contrast, Novartis announced positive Phase III results for Remibrutinib in treating relapsing multiple sclerosis (MS). The oral drug significantly outperformed Sanofi's Aubagio by reducing relapse rates, brain lesions, and disability progression with no signs of liver toxicity.

Actual Topics

To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
Chcete-li se dozvědět více o platformě Dukascopy Bank CFD / Forex, SWFX a dalších souvisejících obchodních informacích, prosím, zavolejte nám, nebo vám můžeme zavolat my.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.